Literature DB >> 7568631

Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze.

T H Privette1, D M Terrian.   

Abstract

The selective kappa agonist U-50,488H was evaluated on the elevated plus-maze test of anxiety. U-50,488H was administered intraperitoneally to male Sprague-Dawley rats 20 min before testing, first in an open field apparatus, then followed immediately on the elevated plus-maze. No significant change in spontaneous locomotor activity was measured in the open field apparatus, suggesting that U-50,488H was devoid of sedative effects in the dose range tested (0.1-1000 micrograms/kg, IP). Doses between 10 and 1000 micrograms/kg produced significant increases in elevated plus-maze behavior that were consistent with anxiolytic actions for U-50,488H. These anxiolytic-like effects were antagonized by naloxone (2.0 mg/kg, IP), suggesting an opioid receptor site of action. In addition, we tested the kappa 1-selective U-50,488H-derivative, U-69,593 (100 micrograms/kg, IP), which was also shown to mimic the anxiolytic-like effects produced by U-50,488H. These results suggest that low doses of the selective kappa 1 agonists U-50,488H and U-69,593 are endowed with anxiolytic properties in rodents and that the kappa opioid system may be involved in the behavioral response to anxiety.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568631     DOI: 10.1007/BF02245945

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  Dynorphin A [1-17] induces "reward" in rats in the place conditioning paradigm.

Authors:  E T Iwamoto
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

Review 2.  The discovery and development of buspirone: a new approach to the treatment of anxiety.

Authors:  J S New
Journal:  Med Res Rev       Date:  1990 Jul-Sep       Impact factor: 12.944

3.  Evaluation of psychotropic drugs with a modified open field test.

Authors:  J M Cunha; J Masur
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

4.  Autoradiography of [3H]U-69593 binding sites in rat brain: evidence for kappa opioid receptor subtypes.

Authors:  B Nock; A Rajpara; L H O'Connor; T J Cicero
Journal:  Eur J Pharmacol       Date:  1988-09-01       Impact factor: 4.432

5.  [3H]U-69593 a highly selective ligand for the opioid kappa receptor.

Authors:  R A Lahti; M M Mickelson; J M McCall; P F Von Voigtlander
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

6.  Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor.

Authors:  A D Corbett; S J Paterson; A T McKnight; J Magnan; H W Kosterlitz
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

7.  Aversive properties of the kappa opioid agonist U50,488 in the week-old rat pup.

Authors:  G A Barr; S Wang; S Carden
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

8.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

9.  Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test.

Authors:  J D Brioni; A B O'Neill; D J Kim; M W Decker
Journal:  Eur J Pharmacol       Date:  1993-07-06       Impact factor: 4.432

10.  A theory of benzodiazepine dependence that can explain whether flumazenil will enhance or reverse the phenomena.

Authors:  S E File; P K Hitchcott
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more
  20 in total

Review 1.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

2.  Adolescent forced swim stress increases social anxiety-like behaviors and alters kappa opioid receptor function in the basolateral amygdala of male rats.

Authors:  E I Varlinskaya; J M Johnson; K R Przybysz; T Deak; M R Diaz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-11-07       Impact factor: 5.067

3.  Atypical anxiolytic-like response to naloxone in benzodiazepine-resistant 129S2/SvHsd mice: role of opioid receptor subtypes.

Authors:  R J Rodgers; R Augar; N Berryman; C J Hansom; M L O'Mahony; R M Palmer; A Stevens; A J Tallett
Journal:  Psychopharmacology (Berl)       Date:  2006-06-27       Impact factor: 4.530

4.  Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females.

Authors:  Cindee F Robles; Marissa Z McMackin; Katharine L Campi; Ian E Doig; Elizabeth Y Takahashi; Michael C Pride; Brian C Trainor
Journal:  Behav Brain Res       Date:  2014-01-18       Impact factor: 3.332

5.  The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors.

Authors:  Maria C Olianas; Simona Dedoni; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

6.  Effect of chronic alcohol vapor exposure on reinstatement of alcohol seeking induced by U50,488.

Authors:  Douglas Funk; Kathleen Coen; Sahar Tamadon; A D Lê
Journal:  Neuropharmacology       Date:  2019-01-16       Impact factor: 5.250

Review 7.  Age as a factor in stress and alcohol interactions: A critical role for the kappa opioid system.

Authors:  Marvin Rafael Diaz; Kathryn Renee Przybysz; Siara K Rouzer
Journal:  Alcohol       Date:  2017-10-12       Impact factor: 2.405

8.  Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats.

Authors:  Akiyoshi Saitoh; Yuji Yoshikawa; Kenji Onodera; Junzo Kamei
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

9.  Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats.

Authors:  Ammar Imad Hazim; Surash Ramanathan; Suhanya Parthasarathy; Mustapha Muzaimi; Sharif Mahsufi Mansor
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.